10-Q · May 14, 2026
MariMed reported Q1 2026 results with a revenue of $39.5 million, surpassing estimates of $38.25 million, while maintaining an EPS loss of $0.01 in line with expectations. The company's net loss improved to $3.8 million…
Earnings analysis · 10-Q
MRMD earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt is limited to controls, legal proceedings, risk factors, and exhibits and does not include the income statement, balance sheet, cash flow statement, or segment disclosures. Controls were deemed…
Read full summary
The provided 10-Q excerpt is limited to controls, legal proceedings, risk factors, and exhibits and does not include the income statement, balance sheet, cash flow statement, or segment disclosures. Controls were deemed effective as of June 30, 2026, with no material changes to internal control during the quarter. The filing reports no material changes to the risk factors from the December 31, 2025 Annual Report, while documenting $8,000,000 of promissory-note principal.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Effective Disclosure Controls
Management concluded that disclosure controls were effective as of June 30, 2026, supporting the timeliness and reliability of reported information.
-
No Material Control Changes
The filing reports no change during the fiscal quarter ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
-
Financing Arrangements Disclosed
The filing identifies two February 24, 2026 promissory notes with principal amounts of $2,000,000 and $6,000,000, documenting the company’s current financing arrangements.
What to watch
-
Debt and Refinancing Exposure
The company has promissory notes totaling $8,000,000 in stated principal—$2,000,000 and $6,000,000—issued on February 24, 2026, creating debt-servicing and refinancing exposure.
-
Regulatory and Litigation Risk
MariMed states that the cannabis industry is highly regulated and that compliance issues can lead to regulatory investigations, litigation, or disciplinary action; the filing also notes increasing cannabis-industry class-action litigation in past years.
-
Employment Claims
The company faces claims from former employees alleging wrongful termination and similar conduct. Although management states these claims are not material, the filing says such claims arise from time to time in the ordinary course.
Management's outlook
The provided 10-Q excerpt contains no quantitative revenue or EPS guidance. Management states that there were no material changes to the risk factors in the Annual Report for the year ended December 31, 2025.
Earlier filings 4
10-K · March 12, 2026
MariMed grew revenue modestly to $159.826M in 2025 (up 1.3% YoY) while generating positive operating cash flow of $7.695M and free cash flow of ~$6.528M. Wholesale expansion (wholesale revenue $69.579M, +10.6%) and…
10-Q · November 6, 2025
MariMed reported essentially flat revenue of $40.76M in Q3 2025 (vs $40.60M in Q3 2024) while gross profit slipped and tax expense surged, producing a larger net loss. Operating income improved modestly to $1.599M, but…
10-Q · August 7, 2025
MariMed reported Q2 revenue of $39,611,000 (down $827,000 or 2.0% YoY from $40,438,000) but up sequentially $1,656,000 (4.4%) from Q1's $37,955,000. Gross margin was 40.5% in Q2 and operating income improved to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.